These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 14599422)

  • 1. [Economic evaluation of pharmacotherapies for smoking cessation].
    Antoñanzas F; Portillo F
    Gac Sanit; 2003; 17(5):393-403. PubMed ID: 14599422
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of pharmacotherapies for nicotine dependence in primary care settings: a multinational comparison.
    Cornuz J; Gilbert A; Pinget C; McDonald P; Slama K; Salto E; Paccaud F
    Tob Control; 2006 Jun; 15(3):152-9. PubMed ID: 16728744
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cost-effectiveness of face-to-face smoking cessation interventions: a dynamic modeling study.
    Feenstra TL; Hamberg-van Reenen HH; Hoogenveen RT; Rutten-van Mölken MP
    Value Health; 2005; 8(3):178-90. PubMed ID: 15877590
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Cost-effectiveness analysis of the first-line therapies for nicotine dependence.
    Cornuz J; Pinget C; Gilbert A; Paccaud F
    Eur J Clin Pharmacol; 2003 Jul; 59(3):201-6. PubMed ID: 12759795
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cost-effectiveness of varenicline versus bupropion, nicotine-replacement therapy, and unaided cessation in Greece.
    Athanasakis K; Igoumenidis M; Karampli E; Vitsou E; Sykara G; Kyriopoulos J
    Clin Ther; 2012 Aug; 34(8):1803-14. PubMed ID: 22818870
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cost utility of bupropion in smoking cessation health programs: simulation model results for Sweden.
    Bolin K; Lindgren B; Willers S
    Chest; 2006 Mar; 129(3):651-60. PubMed ID: 16537864
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost effectiveness of varenicline versus bupropion and unaided cessation for smoking cessation in a cohort of Finnish adult smokers.
    Linden K; Jormanainen V; Linna M; Sintonen H; Wilson K; Kotomäki T
    Curr Med Res Opin; 2010 Mar; 26(3):549-60. PubMed ID: 20050814
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.
    Ekpu VU; Brown AK
    Tob Use Insights; 2015; 8():1-35. PubMed ID: 26242225
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Costs and benefits of smoking cessation aids: making a case for public reimbursement of nicotine replacement therapy in Australia.
    Bertram MY; Lim SS; Wallace AL; Vos T
    Tob Control; 2007 Aug; 16(4):255-60. PubMed ID: 17652241
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of varenicline compared with bupropion, NRT, and nortriptyline for smoking cessation in the Netherlands.
    Hoogendoorn M; Welsing P; Rutten-van Mölken MP
    Curr Med Res Opin; 2008 Jan; 24(1):51-61. PubMed ID: 18021492
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Modelling a budgetary impact analysis for funding drug-based smoking cessation therapies for patients with major depressive disorder in Spain.
    Rejas-Gutiérrez J; Bruguera E; Cedillo S
    Eur Psychiatry; 2017 Sep; 45():41-49. PubMed ID: 28728094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cost-effectiveness of tobacco control policies in Vietnam: the case of personal smoking cessation support.
    Higashi H; Barendregt JJ
    Addiction; 2012 Mar; 107(3):658-70. PubMed ID: 21883602
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of nicotine addiction.
    Jones DL; Mobley CC
    Tex Dent J; 2000 Jun; 117(6):26-32. PubMed ID: 11857853
    [TBL] [Abstract][Full Text] [Related]  

  • 14. New medications for nicotine dependence treatment.
    Hurt RD
    Nicotine Tob Res; 1999; 1 Suppl 2():S175-9; discussion S207-10. PubMed ID: 11768177
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Smoking cessation in a blue-collar population: results from an evidence-based pilot program.
    Ringen K; Anderson N; McAfee T; Zbikowski SM; Fales D
    Am J Ind Med; 2002 Nov; 42(5):367-77. PubMed ID: 12382249
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Cost-effectiveness of pharmacological interventions for smoking cessation: a literature review and a decision analytic analysis.
    Song F; Raftery J; Aveyard P; Hyde C; Barton P; Woolacott N
    Med Decis Making; 2002; 22(5 Suppl):S26-37. PubMed ID: 12369228
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of alternative smoking cessation scenarios in Spain: results from the EQUIPTMOD.
    Trapero-Bertran M; Muñoz C; Coyle K; Coyle D; Lester-George A; Leidl R; Németh B; Cheung KL; Pokhrel S; Lopez-Nicolás Á
    Addiction; 2018 Jun; 113 Suppl 1(Suppl Suppl 1):65-75. PubMed ID: 29532966
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Smoking cessation treatment among dually diagnosed individuals: preliminary evaluation of different pharmacotherapies.
    Saxon AJ; Baer JS; Davis TM; Sloan KL; Malte CA; Fitzgibbons K; Kivlahan DR
    Nicotine Tob Res; 2003 Aug; 5(4):589-96. PubMed ID: 12959797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. First-line pharmacotherapy for tobacco use and dependence.
    Watts SA; Noble SL; Smith PO; Disco M
    J Am Board Fam Pract; 2002; 15(6):489-97. PubMed ID: 12463296
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cost analysis of varenicline versus bupropion, nicotine replacement therapy, and unaided cessation in Nicaragua.
    Lutz MA; Lovato P; Cuesta G
    Hosp Pract (1995); 2012 Feb; 40(1):35-43. PubMed ID: 22406881
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.